Blood urea nitrogen to left ventricular ejection fraction ratio is associated with long-term mortality in the stable

A G Özyıldız1, E Kalaycıoğlu, A Özyıldız

  • 1Department of Cardiology, Recep Tayyip Erdogan University, Training and Research Hospital, Rize, Turkey. aligokhanozyildiz@gmail.com.

Insights

The blood urea nitrogen/left ventricular ejection fraction ratio (BUNLVEFr) effectively predicts mortality and heart failure in stable angina patients. This new indicator offers superior prognostic value compared to BUN or LVEF alone.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Research

Background:

  • Left ventricle (LV) dysfunction is a major cause of mortality in stable angina pectoris (SAP) patients.
  • New prognostic indicators are needed to improve clinical practice for SAP management.
  • Blood urea nitrogen (BUN) is increasingly recognized for its role in cardiovascular diseases, reflecting cardiac dysfunction and neurohormonal activation.

Purpose of the Study:

  • To investigate the prognostic significance of the BUN/LV ejection fraction ratio (BUNLVEFr) for long-term mortality and de novo decompensated heart failure (HF) in SAP patients.
  • To compare the predictive power of BUNLVEFr against BUN and LV ejection fraction (LVEF) alone.

Main Methods:

  • A cohort of 603 consecutive SAP patients undergoing coronary angiography was studied.
  • The median follow-up duration was 112.6 months.
  • Endpoints included all-cause mortality and de novo decompensated HF.

Main Results:

  • Adverse cardiac events occurred in 23.3% of patients, with 17.1% mortality and 6.3% decompensated HF.
  • BUNLVEFr was identified as an independent predictor of mortality and HF (p=0.001).
  • BUNLVEFr demonstrated superior predictive ability compared to BUN alone (p<0.001) and LVEF alone (p<0.001).

Conclusions:

  • The BUNLVEFr ratio offers enhanced prognostic information for SAP patients compared to BUN or LVEF individually.
  • This ratio may aid in refining therapeutic strategies for SAP patients.
  • A BUNLVEFr >29 indicated high sensitivity for predicting mortality/HF.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
138
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
29
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
23
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
229